Japanese Regulatory Agency Licenses Certara’s Phoenix and Simcyp Software to Support Model-based Drug Development
PRINCETON, NJ – Feb. 26, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is equipping its pharmacometrics team with Certara’s Phoenix® biosimulation solutions and its Simcyp™ Population-based Simulator. PMDA joins FDA and several other global regulatory agencies in increasing its reliance on biosimulation for investigational new drug and new drug approval reviews.
“Biosimulation is now consistently relied upon by regulatory agencies’ pharmacometrics teams in pre-clinical, clinical and post-approval drug development decisions,” said Certara CEO Edmundo Muniz, M.D., Ph.D. “Furthermore, a paper and survey from the International Consortium for Innovation and Quality in Pharmaceutical Development published by the American Association of Pharmaceutical Scientists last month stated that Phoenix was used by 100 percent of the 22 leading pharmaceutical companies surveyed, and 86 percent of them were using Simcyp. These percentages placed Certara’s offerings as the #1 and #2 ranked biosimulation solutions. We are proud to be working with PMDA, as it advances the use of these innovative modeling approaches from regulatory science to regulatory approval.”
PMDA is using PPK (population pharmacokinetic), PK/PD (pharmacokinetic/pharmacodynamic), and other modeling and biosimulation approaches for dosage, dose regimen and dose adjustment for special populations, including pediatrics. In addition, PKS Online will provide the technical infrastructure necessary to securely store and manage PK and PD study data, and the associated pharmacometric analyses, in a regulatory-compliant environment.
Certara’s Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for the prediction of drug-drug interactions, assisting in dose selection, and informing clinical decisions related to product labeling. Simcyp whole body simulation methodology can predict the pharmacokinetics of drug compounds and proteins based on in vitro data. The simulator includes a unique set of genetic, physiological and epidemiological databases that facilitate the simulation of virtual populations from around the globe.
In addition to PMDA, all leading Japanese pharmaceutical companies have integrated both the Phoenix and Simcyp biosimulation solutions into their drug development workflow.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
